Australia markets open in 9 hours 27 minutes

Vivoryon Therapeutics N.V. (VVY.AS)

Amsterdam - Amsterdam Delayed price. Currency in EUR
Add to watchlist
1.3140+0.4930 (+60.05%)
As of 04:17PM CEST. Market open.
Full screen
Previous close0.8210
Open0.9000
BidN/A x N/A
AskN/A x N/A
Day's range0.9000 - 1.4080
52-week range0.4100 - 16.9000
Volume5,158,350
Avg. volume856,600
Market cap34.252M
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease

    Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company’s futureVaroglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity and subgroup analys

  • GlobeNewswire

    Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024

    Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle (Saale) / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ended March

  • GlobeNewswire

    Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024

    Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich, Germany, May 08, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2024 Annual General Meeting will be held on Friday, June 21, 2024 at 01:00 p.m. (CEST) at the A